2026 Step Therapy Prior Authorization for select outpatient drugs
Customize your policy alerts
Sign up for all harvard pilgrim health care policy alerts
Know when harvard pilgrim health care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Step Therapy requirements for specific outpatient prescription drugs for Tufts Health One Care (HMO D-SNP) members, indicating which products are Step-1 (no prior authorization) vs Step-2 (require previous fill of Step-1/Step-2 agents). Affects providers and pharmacists prescribing or dispensing the listed products.
No material clinical or coverage changes in this revision.
Step Therapy Coverage Criteria by Drug Class
Antidepressant Step Therapy
Antidepressant products
Evidence: paid pharmacy claim or physician documentation within 180 days.
Atypical Antipsychotics Step Therapy
Atypical antipsychotic products
Evidence: paid pharmacy claim or physician documentation within 180 days.
Inhaled Steroids Step Therapy
Inhaled corticosteroid products
Evidence: paid pharmacy claim or physician documentation within 180 days.
MS Therapies Step Therapy
Multiple sclerosis disease-modifying therapies
Evidence: two or more paid pharmacy claims or physician documentation within 180 days.
| Requirement | Acceptable evidence | Lookback period / required fills |
|---|---|---|
| Step therapy prior-fill requirement for Step-2 agents | Paid pharmacy claim showing a fill for the required Step-1 or Step-2 medication or physician documentation confirming the prior fill(s) | 180 days (lookback). Generally 1 prior fill required; Rebif/Rebif Rebidose require 2 prior Step-1 fills. |
Operational Coding & Lookback
Provider Requirements, Documentation, and Denial Risks
General Step Therapy requirement
Step therapy is enforced: specified Step-1 agents are covered without prior authorization; specified Step-2 agents require prior evidence of fills within a 180-day lookback. The number of required prior fills varies by drug group (usually one; Rebif requires two).
- Step-1 agents listed in the policy are covered without prior authorization.
- Step-2 agents require evidence of prior use of one or more Step-1 (or Step-2 where specified) medications within the previous 180 days.
- Rebif and Rebif Rebidose require two or more Step-1 medication fills in the 180-day lookback.
Antidepressant Step Therapy — prior fill required
Coverage for Emsam, Fetzima, and Exxua (Step-2 antidepressants) requires documentation of a prior Step-1 or Step-2 medication fill within the previous 180 days; without this evidence coverage will not be granted.
- Acceptable evidence: paid pharmacy claim or physician documentation showing a fill within the prior 180 days.
Atypical antipsychotic Step Therapy — prior fill required
Coverage for Asenapine and Fanapt (Step-2 atypical antipsychotics) requires evidence of one or more Step-1 or Step-2 medication fills within the previous 180 days as shown by a paid claim or physician documentation.
- Provide a paid pharmacy claim or physician documentation demonstrating the required fill(s) within 180 days.
Inhaled steroid Step Therapy — Fluticasone prior fill required
Fluticasone (Step-2 inhaled steroid) will be covered only if there is evidence of a Step-1 medication fill within the previous 180 days; submit a paid claim or physician documentation to demonstrate prior use.
- QVAR is Step-1 and is covered without authorization; Fluticasone requires the Step-1 fill lookback.
MS therapy Step Therapy — two prior Step-1 fills required
Rebif and Rebif Rebidose (Step-2 MS therapies) require evidence of two or more Step-1 medication fills within the previous 180 days for coverage; provide paid pharmacy claims or physician documentation to meet this requirement.
- Avonex, Betaseron, and Plegridy are Step-1 (covered without prior authorization).
- Rebif products require two or more Step-1 fills in the 180-day lookback.
Evidence to support prior therapy
Physician documentation or a paid pharmacy claim within the previous 180 days demonstrating a fill for the required Step-1 or Step-2 medication(s) must be submitted to support Step-2 coverage requests.
- Documentation must clearly identify the medication and date of fill within the 180-day lookback.
Denial risk — Step-2 antidepressants
Coverage for Step-2 agents (for example, Emsam, Fetzima, Exxua) will be denied unless the member has a paid claim or physician documentation showing prior therapy with a Step-1 or Step-2 medication within the previous 180 days.
- If no acceptable evidence of prior fill is provided within 180 days, the request should be denied per policy.
Denial risk — Step-2 atypical antipsychotics
Coverage for Asenapine and Fanapt will be denied unless the member has filled one or more Step-1 or Step-2 medications within the previous 180 days as evidenced by a paid claim or physician documentation.
- Absent acceptable prior-fill evidence within the 180-day lookback, coverage must be denied.
Denial risk — Fluticasone (inhaled steroid)
Coverage for Fluticasone will be denied unless the member has a paid claim or physician documentation showing a Step-1 medication fill within the previous 180 days.
- QVAR is Step-1 (no prior authorization); Fluticasone requires proof of Step-1 fill in the lookback to avoid denial.
Denial risk — Rebif products (interferons)
Coverage for Rebif and Rebif Rebidose requires evidence of two or more Step-1 medication fills within the previous 180 days; without such evidence, coverage will be denied.
- Submit paid pharmacy claims or physician documentation demonstrating two or more Step-1 fills within 180 days to meet the requirement.
Policy Background and Scope
This document is a formulary-based step therapy guideline for select outpatient prescription drugs used by Tufts Health One Care (HMO D‑SNP) members. It defines which products are designated Step‑1 (covered without prior authorization) and which are Step‑2 (require evidence of prior therapy) across multiple therapeutic categories including antidepressants, atypical antipsychotics, inhaled corticosteroids, and multiple sclerosis disease‑modifying therapies. The policy is effective 06/01/26 and applies to the products listed in the formulary.
For Step‑2 coverage the policy requires documentation of prior use as described for each drug group: coverage is granted only when a paid pharmacy claim or physician documentation shows the required prior fills within the policy’s lookback period. The standard lookback period is 180 days; the number of required fills varies by drug group (usually one prior fill, except Rebif products which require two prior Step‑1 fills).
Operationally, specified Step‑1 agents are available to members without prior authorization and help resolve first‑line prescribing. Specified Step‑2 agents may be covered only after the member meets the stated prior‑therapy requirements documented by a paid claim or physician attestation within the 180‑day window; absent that evidence, claims for Step‑2 agents are subject to denial.
Step Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.